Loading…
Cabaletta Bio, Inc. is projected to rise to $3.10 by 2027, a +4% move from its current price of $2.98. CABA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.88 | $2.98 | $3.07 | 0.00% |
| Jul 13 | $2.84 | $2.98 | $3.12 | 0.00% |
| Jul 14 | $2.81 | $2.98 | $3.15 | 0.00% |
| Jul 15 | $2.79 | $2.98 | $3.18 | 0.00% |
| Jul 16 | $2.77 | $2.98 | $3.20 | +0.01% |
| Jul 17 | $2.75 | $2.98 | $3.22 | +0.01% |
| Jul 18 | $2.73 | $2.98 | $3.24 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.73 | $2.98 | $3.24 | +0.01% |
| Week 2 | $2.63 | $2.98 | $3.36 | +0.01% |
| Week 3 | $2.56 | $2.98 | $3.46 | +0.02% |
| Week 4 | $2.50 | $2.98 | $3.54 | +0.03% |
| Week 5 | $2.45 | $2.98 | $3.61 | +0.04% |
| Week 6 | $2.41 | $2.98 | $3.68 | +0.04% |
| Week 7 | $2.37 | $2.98 | $3.74 | +0.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune diseases. It is headquartered in Philadelphia, Pennsylvania, and was incorporated in 2017.
The company previously operated as Tycho Therapeutics and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for a broad set of autoimmune conditions including dermatomyositis and systemic lupus erythematosus, among others.
In addition to resecabtagene autoleucel, Cabaletta is developing DSG3-CAART, a CAAR T cell therapy in Phase 1 trials for mucosal pemphigus vulgaris, and MuSK-CAART, another investigational cell therapy in Phase 1 for anti-MuSK antibody positive myasthenia gravis. The company has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia, as well as Nanjing IASO Biotherapeutics Co., Ltd, Oxford Biomedica, Autolus Holdings (UK) Limited, and WuXi Advanced Therapies, Inc.}
Cabaletta Bio, Inc. (CABA) trades at $3.01 per share and holds a market capitalization of $490.79M. It is ranked 3026 by market capitalization among listed assets. The current price sits within a broader, forecasted path of upside over the coming years.
The long-range outlook envisions higher averages and notable upside, with the max forecast price reaching $42.12 by 2050 and an average forecast price of $19.98 in 2050, implying substantial potential upside from today’s level.
Near-term, the forecast shows a gradual climb in value with a 2026 average price of $3.01 and a path toward higher levels through 2030 and beyond. The upper-bound forecast by 2050 suggests meaningful appreciation relative to today’s price, supported by a multi-year rise in average prices and rising ROI metrics through the forecast horizon.}
A major floor 25.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
The nearest ceiling, 27.1% above — a clean break opens room to run.
A major ceiling 40.0% above — clearing it would confirm fresh momentum.
Key CABA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CABA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.07 | Sell | $3.06 | Sell |
| MA 10 | $3.08 | Sell | $3.06 | Sell |
| MA 20 | $3.01 | Sell | $3.10 | Sell |
| MA 50 | $3.32 | Sell | $3.17 | Sell |
| MA 100 | $3.21 | Sell | $3.10 | Sell |
| MA 200 | $2.84 | Buy | $2.96 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.58 | Neutral |
| Stoch RSI (14) | 40.42 | Neutral |
| CCI (20) | -34.80 | Neutral |
| Williams %R (14) | -79.63 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -1.49 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 20.37 | Neutral |
| TRIX (15) | -0.40 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 44.10 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 3.08 | Sell |
| ADX (14) | 13.20 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is neutral. RSI(14) stands at 40, indicating modest momentum and no overbought conditions.
The stock trades above the 200-day simple moving average (SMA200) at $2.72 and near the 50-day simple moving average (SMA50) at $3.36, suggesting a mixed near-term trend with potential for sideways movement.
Support is identified at $2.94 and resistance at $4.15. The 30-day price range spans from $2.35 to $3.86, illustrating limited upside within the near term and continued volatility.}
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.04 | $2.98 | $3.62 | 0% | Neutral | |
| $2.42 | $3.10 | $4.22 | +4% | Neutral | |
| $2.81 | $3.72 | $5.28 | +25% | Bullish | |
| $3.18 | $4.33 | $6.37 | +46% | Bullish | |
| $3.13 | $4.37 | $6.60 | +47% | Bullish | |
| $3.17 | $4.52 | $7.01 | +52% | Bullish | |
| $3.16 | $4.62 | $7.31 | +55% | Bullish | |
| $3.06 | $4.57 | $7.37 | +53% | Bullish | |
| $3.27 | $4.97 | $8.17 | +67% | Bullish | |
| $3.62 | $5.60 | $9.37 | +88% | Bullish | |
| $4.40 | $7.42 | $13.31 | +150% | Bullish | |
| $7.76 | $15.20 | $30.14 | +411% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.04 | $2.98 | $3.61 | +0.00% |
| August 2026 | $2.49 | $2.95 | $3.61 | -0.75% |
| September 2026 | $2.49 | $2.98 | $3.69 | +0.85% |
| October 2026 | $2.53 | $3.06 | $3.83 | +2.60% |
| November 2026 | $2.44 | $2.97 | $3.75 | -2.95% |
| December 2026 | $2.33 | $2.84 | $3.62 | -4.20% |
Click any year to see its month-by-month CABA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cabaletta Bio, Inc.'s 2026 outlook centres on $2.98, within a $2.04 to $3.62 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CABA could reach as high as $4.22, with a base case around $3.10 and support toward $2.42 — roughly +4% from $2.98. A consolidation phase looks the most probable path here.
Expect CABA to range from $2.81 to $5.28 through 2028. The $3.72 average target implies a +25% move from current prices. That is up +20% on the projected 2027 average. Momentum favours further upside here.
The CABA price prediction for 2029 points to an average of $4.33 (low $3.18, high $6.37) — a potential gain of +46% on today's $2.98. Buyers look set to stay in control over this stretch.
In 2030, CABA is projected to trade between $3.13 and $6.60, averaging $4.37 — a potential gain of +47% from today's $2.98. That is up +1% on the projected 2029 average. Momentum favours further upside here.
Cabaletta Bio, Inc.'s 2031 outlook centres on $4.52, within a $3.17 to $7.01 range. That is up +4% on the projected 2030 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CABA could reach as high as $7.31, with a base case around $4.62 and support toward $3.16 — roughly +55% from $2.98. Momentum favours further upside here.
Expect CABA to range from $3.06 to $7.37 through 2033. The $4.57 average target implies a +53% move from current prices. That is -1% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The CABA price prediction for 2034 points to an average of $4.97 (low $3.27, high $8.17) — a potential gain of +67% on today's $2.98. Momentum favours further upside here.
In 2035, CABA is projected to trade between $3.62 and $9.37, averaging $5.60 — a potential gain of +88% from today's $2.98. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cabaletta Bio, Inc.'s 2040 outlook centres on $7.42, within a $4.40 to $13.31 range. That is up +32% on the projected 2035 average. That marks a +150% change versus current levels. Momentum favours further upside here.
By 2050, CABA could reach as high as $30.14, with a base case around $15.20 and support toward $7.76 — roughly +411% from $2.98. Buyers look set to stay in control over this stretch.
Investing $1,000 in CABA today (≈ 336.134454 CABA) could be worth
$5,110.07
+$4,110.07 (+411%) by 2050 · US Dollar
Based on the average projected CABA price of $15.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CABAwould be worth at today's price.
$1,000 invested in CABA on Jul 10, 2025 (≈ 574.712641 CABA) would be worth
$1,709.77
+$709.77 (+71.0%) today · 1.71× · US Dollar
Based on a CABA entry price of $1.74 vs. today's $2.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.19 | $932.6 | -6.7% |
| 1 month ago | $3.04 | $978.62 | -2.1% |
| 3 months ago | $3.13 | $950.48 | -5.0% |
| 6 months ago | $2.21 | $1,346.15 | +34.6% |
| 1 year ago | $1.74 | $1,709.77 | +71.0% |
| All time (5.0y) ago | $8.17 | $364.14 | -63.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CABA forecast.
Our base-case forecast reaches $6.00 around 2040.
Implied market cap at $6.00: $978.33M
The multi-year forecast shows bullish dynamics extending through 2031 and beyond, with the average price rising from $3.01 in 2026 to higher levels over time. Notably, the 2027 average is $3.44 and the 2030 average is $4.93, with a continued ascent to $8.79 by 2040 and $19.98 by 2050.
The forecast also highlights strong upside in ROI, rising from 0 in 2026 to 14.3 in 2027, 34.3 in 2028, 64.3 in 2029, 63.9 in 2030, 64 in 2031, 81.1 in 2032, 71.3 in 2033, 86.8 in 2034, 140.6 in 2035, 192.2 in 2040, and 563.8 in 2050.
By 2030 the average price is projected at $4.93 with a max of $7.74, by 2040 the average is projected at $8.79 with a max of $16.62, and by 2050 the average is $19.98 with a max of $42.12. These figures illustrate a sustained bullish trajectory, balanced by the inherent uncertainty of long-range projections.
Risks include the inherent uncertainty in long-range forecasts and the fact that these are estimates rather than guarantees. Market movements, clinical trial outcomes, and regulatory developments can all sway actual results away from the projected path.}
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.93, a minimum of $3.41, and a maximum of $7.74, with an ROI of 63.9.
Forecasts indicate a bullish path beyond 2026, with rising averages and higher upside potential (e.g., 2030 avg $4.93; 2050 avg $19.98 and max $42.12), but these are estimates and not guarantees. The 2026 ROI is 0 and the years that follow show positive ROIs according to the forecast.
Yes, the 2050 forecast shows an average of $19.98 and a max of $42.12, indicating that crossing the $20 level is within the forecasted upside by 2050.
The current price is $3.01 and the market capitalization is $490.79M.
Momentum is neutral with RSI(14) at 40. The SMA50 is $3.36 and the SMA200 is $2.72. Support is at $2.94 and resistance at $4.15, with a 30-day price range from $2.35 to $3.86.
Cabaletta Bio, Inc. Community Discussion
0Share your Cabaletta Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.